Interim Analysis Demonstrates Reassuring Toxicity Profile for Glioblastoma
July 24th 2020David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm
February 10th 2016David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.